Last reviewed · How we verify
ALT-803
ALT-803 is an IL-15 superagonist that stimulates the expansion of natural killer cells and CD8+ T cells.
ALT-803 is an IL-15 superagonist that stimulates the expansion of natural killer cells and CD8+ T cells. Used for Relapsed or refractory acute myeloid leukemia (AML), Relapsed or refractory multiple myeloma.
At a glance
| Generic name | ALT-803 |
|---|---|
| Also known as | IL-15 superagonist, Super-agonist IL-15, IL-15 |
| Sponsor | ImmunityBio, Inc. |
| Drug class | IL-15 superagonist |
| Target | IL-15 receptor complex |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ALT-803 works by binding to the IL-15 receptor complex, which activates the JAK/STAT signaling pathway and promotes the proliferation and activation of natural killer cells and CD8+ T cells. This leads to enhanced anti-tumor activity and improved immune response.
Approved indications
- Relapsed or refractory acute myeloid leukemia (AML)
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- A Study to Assess Anktiva in Patients With Long Covid-19. (PHASE2)
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (PHASE1)
- A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (PHASE1, PHASE2)
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer (PHASE1)
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALT-803 CI brief — competitive landscape report
- ALT-803 updates RSS · CI watch RSS
- ImmunityBio, Inc. portfolio CI